Abstract
Prurigo nodularis is a pruritic dermatosis of unknown origin. Human T-cell lymphotropic virus type 1 (HTLV-1) causes adult T-cell leukaemia/lymphoma. HTLV-1 is not considered to be a cause of prurigo nodularis. A 52-year-old black man, from the French West Indies, who had had prurigo nodularis for 12 years, presented with a distinct micropapular eruption with the typical pathological picture of epidermotropic T-cell lymphoma. Based on HTLV-1-positive serology and monoclonal integration of HTLV-1 we diagnosed smouldering adult T-cell leukaemia/lymphoma. Re-examination of previous skin biopsies revealed that the disease had been evolving for 12 years. Treatment with alpha-interferon, 3 x 106 units three times a week, associated with zidovudine, 1 g daily, resulted in complete remission within 4 months. When investigating a prurigo nodularis, we therefore recommend: (i) performing HTLV-1 serology if the patient comes from an endemic area; (ii) if positive, performing CD25 staining and looking for a HTLV-1 clonal integration; and (iii) if positive, using a treatment targeting HTLV-1.
MeSH terms
-
Anemia, Refractory, with Excess of Blasts / drug therapy
-
Anemia, Refractory, with Excess of Blasts / pathology
-
Anemia, Refractory, with Excess of Blasts / virology*
-
Antineoplastic Agents / therapeutic use
-
Antiviral Agents / therapeutic use
-
Biopsy
-
CD4-Positive T-Lymphocytes / immunology
-
CD4-Positive T-Lymphocytes / virology
-
Human T-lymphotropic virus 1 / genetics
-
Human T-lymphotropic virus 1 / immunology
-
Human T-lymphotropic virus 1 / pathogenicity*
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Interleukin-2 Receptor alpha Subunit / analysis
-
Leukemia-Lymphoma, Adult T-Cell / complications
-
Leukemia-Lymphoma, Adult T-Cell / diagnosis*
-
Leukemia-Lymphoma, Adult T-Cell / drug therapy
-
Leukemia-Lymphoma, Adult T-Cell / immunology
-
Male
-
Middle Aged
-
Prurigo / drug therapy
-
Prurigo / immunology
-
Prurigo / pathology
-
Prurigo / virology*
-
Recombinant Proteins
-
Skin / immunology
-
Skin / pathology
-
Skin / virology*
-
Time Factors
-
Treatment Outcome
-
Zidovudine / therapeutic use
Substances
-
Antineoplastic Agents
-
Antiviral Agents
-
IL2RA protein, human
-
Interferon alpha-2
-
Interferon-alpha
-
Interleukin-2 Receptor alpha Subunit
-
Recombinant Proteins
-
Zidovudine